Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition

2 days ago 2

Maham Fatima

Thu, December 11, 2025 astatine 6:44 AM CST 2 min read

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is 1 of the high abbreviated involvement stocks to bargain close now. On December 9, Morgan Stanley expert Michael Ulz raised the firm’s terms people connected Mirum Pharmaceuticals to $95 from $81 with an Overweight standing connected the shares. Ulz informed investors that the acquisition of Bluejay is important due to the fact that it adds the cause brelovitug to the pipeline. Brelovitug has shown promising enactment and tolerability successful treating hepatitis delta microorganism and volition grow the company’s uncommon liver illness pipeline portion besides creating invaluable synergies.

In its Q3 2025 net report, Mirum Pharmaceuticals’ quarterly gross totaled $133 million, which marked a ~50% year-over-year increase. This beardown show highlighted the operating leverage successful its commercialized model, resulting successful a affirmative nett income of ~$3 cardinal for the quarter. The superior operator of gross was the company’s merchandise sales. LIVMARLI nett merchandise income totaled $92 cardinal for the quarter, breached down into $64 cardinal successful US income and $28 cardinal successful International sales. Sales of Bile Acid Medicines contributed an further $41 cardinal successful nett merchandise sales.

Morgan Stanley Raises Mirum (MIRM) PT to $95 connected Strategic Bluejay Acquisition, Brelovitug Pipeline Addition

Despite the beardown performance, the institution faces immoderate commercialized variability, peculiarly with LIVMARLI’s planetary income owed to periodic ample orders from distributors. Management anticipates a sequential diminution successful gross for Q4 and does not expect further income to its partner, Takeda, successful Japan during that quarter, which had contributed to the Q3 revenue. The institution is besides facing uncertainty regarding the due pricing strategy for its investigational drug, volixibat, arsenic it continues to analyse marketplace dynamics, considering analogs from different PBC treatments.

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is simply a biopharmaceutical institution that develops and commercializes caller therapies for debilitating uncommon and orphan diseases.

While we admit the imaginable of MIRM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.